Plans to file an IND and begin a Phase 1/2 trial for SC451 as early as this year; first-in-human data for SG293 in non-Hodgkin lymphoma targeted as early as this year.
CEO Steve Harr said the company expects clinical insight on SC451 and SG293 over the next 6–9 months, if development proceeds as anticipated.
Second-quarter results and cash position
Sana Biotechnology posted a GAAP net loss of USD 63.6 million, or USD 0.22 a share, for Q2 2026.
Cash, cash equivalents, and marketable securities rose to USD 160.5 million as of June 30, 2026; runway expected into mid-2027.
R&D expense increased to USD 30.7 million from USD 29.8 million a year earlier, on higher SC451 and SG293 development and CDMO costs.
SANA•
